| CAS NO: | 2743-90-0 |
| 包装 | 价格(元) |
| 10mg (solution) | 电议 |
| 50mg (solution) | 电议 |
| 100mg (solution) | 电议 |
| Physical Appearance | A solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. |
| Storage | Store at -20°C |
| M.Wt | 160.2 |
| Cas No. | 2743-90-0 |
| Formula | C10H12N2 |
| Solubility | ≤15mg/ml in DMSO;15mg/ml in dimethyl formamide |
| Chemical Name | 1,2,3,6-tetrahydro-2,3'-bipyridine |
| Canonical SMILES | [C@@H]1(C2=CN=CC=C2)CC=CCN1 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Anatabine, an alkaloid with a chemical structural similarity to nicotine, is a minor tobacco alkaloid produced in plants of the Solanacea family including tobacco, green tomatoes, peppers and eggplants [1]. (R,S)-Anatabine is an Aβ inhibitor [1].
Aβ peptides play a dominant role in the development of Alzheimer's disease. Natural soluble Aβ oligomers and more specifically Aβ dimers isolated from Alzheimer's disease brains have been involved in inducing tau hyperphosphorylation and neuritic degeneration, which results in the accumulation of Aβ oligomers to the neurofibrillary degeneration observed in Alzheimer's disease [1].
In vitro: Anatabine dose-dependently lowered Aβ1-40 and Aβ1-42 levels and reduced sAPPβ production without any effects on sAPPα levels. Anatabine lowered Aβ production by mainly impacting the β-cleavage of APP. Anatabine lowered NFκB activation. Anatabine inhibited BACE-1 transcription and reduced BACE-1 protein levels in human neuronal like SHSY-5Y cells. (R,S)-Anatabine also dose dependently inhibits NF-κB activation [1].
In vivo: In a transgenic mouse model of Alzheimer's disease, acute treatment with anatabine for 4 days significantly lowered brain soluble Aβ1-40 and Aβ1-42 levels [1].
Reference:
[1] Paris D, Beaulieu-Abdelahad D, Bachmeier C, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo[J]. European journal of pharmacology, 2011, 670(2): 384-391.
m.cnreagent.com